WASHINGTON, Aug. 17 (UPI) -- The U.S. Food and Drug Administration announced the recall of a Barr Laboratories Inc. amphetamine product because of a health hazard.
The FDA said the dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate 20mg mixed amphetamine salt tablets are being recalled because some might exceed weight requirements, resulting in super-potency.
The federal agency said potential adverse reactions to a supratherapeutic dose could include cardiovascular, neurologic, psychiatric and gastrointestinal reactions such as: palpitations, euphoria, tachycardia, hypertension, headache, tremor, anxiety and decreased appetite.
"This product can be uniquely identified as an oval peach colored tablet, debossed with "b/973" on one side and "2/0" on the other side," the FDA said, noting the company distributed the affected lot between June 11 and June 16. Only lot 311756 is affected by the recall.
Consumers with questions can call 888-742-5578.
